---
title: "Zai Lab Q4 Earnings Summary & Key Takeaways"
description: "Zai Lab (NASDAQ:ZLAB) reported Q4 earnings on February 26, 2026, beating estimates by 206.98% with an EPS of $0.46, compared to an estimate of $-0.43. Revenue increased by $18.53 million year-over-yea"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/277038344.md"
published_at: "2026-02-26T12:10:20.000Z"
---

# Zai Lab Q4 Earnings Summary & Key Takeaways

> Zai Lab (NASDAQ:ZLAB) reported Q4 earnings on February 26, 2026, beating estimates by 206.98% with an EPS of $0.46, compared to an estimate of $-0.43. Revenue increased by $18.53 million year-over-year. In the previous quarter, Zai Lab missed EPS estimates by $0.04, leading to a 5.4% drop in share price. Historical performance shows fluctuations in EPS and revenue across the last four quarters. For more details, visit Zai Lab's earnings calendar.

The Q4 earnings report for **Zai Lab** (NASDAQ:ZLAB) was released on Thursday, February 26, 2026 at 07:00 AM.

Here's what investors need to know about the latest announcement.

### Earnings

Zai Lab beat estimated earnings by 206.98%, reporting an EPS of $0.46 versus an estimate of $-0.43.

Revenue was up $18.53 million from the same period last year.

### Performance in Previous Earnings

The company missed on EPS by $0.04 in the last quarter, resulting in a 5.4% drop share price change the following day.

Here's a look at Zai Lab's past performance:

**Quarter**

**Q3 2025**

**Q2 2025**

**Q1 2025**

**Q4 2024**

**EPS Estimate**

\-0.29

\-0.40

\-0.55

\-0.07

**EPS Actual**

\-0.33

\-0.37

\-0.45

\-0.80

**Revenue Estimate**

144.16M

126.09M

115.86M

108.17M

**Revenue Actual**

116.09M

109.98M

106.49M

109.07M

To track all earnings releases for Zai Lab visit their earnings calendar here.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

### Related Stocks

- [IBBQ.US - Invesco Nasdaq Biotechnology ETF](https://longbridge.com/en/quote/IBBQ.US.md)
- [BIB.US - Proshares Ultra Nasdaq Biotech](https://longbridge.com/en/quote/BIB.US.md)
- [PBE.US - Invesco Biotechnology & Genome ETF](https://longbridge.com/en/quote/PBE.US.md)
- [SBIO.US - ALPS Medical Breakthrough](https://longbridge.com/en/quote/SBIO.US.md)
- [XBI.US - SPDR S&P Biotech](https://longbridge.com/en/quote/XBI.US.md)
- [ARKG.US - Ark Genomic Revolution ETF](https://longbridge.com/en/quote/ARKG.US.md)
- [FBT.US - First Trust NYSE Arca Biotech Index Fd](https://longbridge.com/en/quote/FBT.US.md)
- [IHE.US - iShares US Pharma](https://longbridge.com/en/quote/IHE.US.md)
- [IBB.US - iShares Biotechnology ETF](https://longbridge.com/en/quote/IBB.US.md)
- [VHT.US - VG Health](https://longbridge.com/en/quote/VHT.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 深入分析 Rhythm Pharmaceuticals 第四季度的財報表現 | Rhythm Pharmaceuticals（納斯達克代碼：RYTM）於 2026 年 2 月 26 日公佈了第四季度財報，盈利超出預期 6.41%，每股收益為-0.73 美元，而預期為-0.78 美元。收入同比增長 1542 萬美元。在上 | [Link](https://longbridge.com/en/news/277036576.md) |
| 深入瞭解 Maravai LifeSciences 第四季度的財報表現 | Maravai LifeSciences（納斯達克代碼：MRVI）於 2026 年 2 月 25 日公佈了其第四季度財報，盈利超出預期 50%，每股收益為-$0.04，而預期為-$0.08。然而，收入同比下降了 669 萬美元。在上一季度， | [Link](https://longbridge.com/en/news/276938780.md) |
| Fate Therapeutics 第四季度財報總結及主要內容 | Fate Therapeutics（納斯達克代碼：FATE）於 2026 年 2 月 26 日公佈了第四季度財報，實際每股收益（EPS）為-0.27，未能達到預期。與去年相比，收入減少了 491,000 美元。在上一個季度，公司每股收益超出 | [Link](https://longbridge.com/en/news/277057214.md) |
| Amphastar 製藥第四季度收入未達市場預期 | Amphastar Pharmaceuticals 報告第四季度收入為 1.8311 億美元，未達到分析師預期的 1.9048 億美元。調整後的每股收益也低於預期，為 0.73 美元，而預期為 0.92 美元。由於美國市場營銷力度增加，BA | [Link](https://longbridge.com/en/news/277102773.md) |
| ImmunityBio 超越預期，實現收入五倍增長 | ImmunityBio Inc.（納斯達克代碼：IBRX）報告稱，收入增長了五倍，主要得益於 Anktiva 銷售激增 750%，達到 3829 萬美元，超出預期。該公司已與合作伙伴達成協議，在沙特阿拉伯及中東和北非地區推出 Anktiva | [Link](https://longbridge.com/en/news/276923608.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.